Generated by AI
vTv Therapeutics Inc. Class A Common Stock represents equity in vTv Therapeutics, a late-stage biopharmaceutical company focused on developing oral small-molecule therapies for diabetes and other chronic diseases. The company’s current pipeline centers on treatments designed to address metabolic and inflammatory conditions, with particular emphasis on diabetes-related programs and other areas of unmet medical need. vTv Therapeutics works primarily through the discovery and clinical development of drug candidates intended for oral administration, a format that supports convenient long-term use in chronic disease care. Its business is concentrated on advancing proprietary therapeutic programs rather than commercial product sales, making the company a development-stage participant in the biotechnology sector. vTv Therapeutics is headquartered in High Point, North Carolina, and its Class A common stock is its primary public equity class.
Website3980 Premier Drive
High Point, NC, 27265
United States
The latest articles about VTVT.
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) completed enrollment with 166 participants randomized; topline results expected mid 2027 Randomized the first participant in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in individuals with T1D who use hybrid closed-loop (HCL) insulin delivery systems Company hosted a Key Opinion Leader (KOL) event in October, highlighting cadisegliatin and its potential to address hypoglycemia in people wit
Summary of Oct 5's posts. Generated by AI.
Summary of Mar 17's posts. Generated by AI.
Summary of Feb 18's posts. Generated by AI.
Summary of Feb 28's posts. Generated by AI.
Investors talking about VTVT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.